sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has made an opening position disclosure regarding its interests in Avadel Pharmaceuticals plc. As of November 25, 2025, Vanguard holds a significant stake in Avadel, with 5,576,808 ordinary shares representing 5.73% of the company. This disclosure is compliant with the Irish Takeover Panel rules under the Panel's Act of 1997.
The disclosure revealed a recent purchase of 4,554 US$0.01 ordinary shares at a unit price of 22.93 USD. No dealings were reported in cash-settled or stock-settled derivatives involving Avadel's securities.
No indemnity or option arrangements have been reported, and there are no agreements influencing voting rights or future transactions involving Avadel's securities.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.